Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma. 1985

J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002064 Buserelin A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications. Bigonist,Buserelin Acetate,HOE-766,Profact,Receptal,Suprecur,Suprefact,Tiloryth,Acetate, Buserelin,HOE 766,HOE766
D003534 Cyproterone An anti-androgen that, in the form of its acetate (CYPROTERONE ACETATE), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. Cyproterone, 1alpha,2 alpha,9 beta,10 alpha-Isomer
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
July 1993, Cancer,
J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
January 1978, Scandinavian journal of urology and nephrology,
J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
May 1987, The Journal of urology,
J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
January 1996, Khirurgiia,
J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
January 1973, The Journal of urology,
J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
November 1980, The Journal of clinical endocrinology and metabolism,
J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
January 1997, International urology and nephrology,
J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
January 1989, European urology,
J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
February 1995, Lancet (London, England),
J G Klign, and H J de Voogt, and F H Schröder, and F H de Jong
June 1989, BMJ (Clinical research ed.),
Copied contents to your clipboard!